Oura is integrating its Menopause Impact Scale (MIS) into clinical workflows through partners across menopause care, primary care, employer benefits, telehealth, and hormone tracking.
Launched in May, MIS is a clinically validated questionnaire that measures how menopause affects quality of life. The assessment, completed by over 600,000 Oura members, tracks seven symptom domains, including cognition, body image, sexual function and vaginal symptoms, musculoskeletal pain, hot flashes, sleep maintenance, and urinary tract symptoms.
“Women navigating menopause can find themselves explaining the same symptoms to different providers, while the true impact on their daily lives gets reduced to a snapshot in time,” said Dorothy Kilroy, Chief Commercial Officer at Oura. “That’s why we developed the MIS: to give women and their providers a consistent way to track menopause’s impact over time.”
With the new integrations, Oura’s MIS extends into real-world clinical workflows to help inform care plans. Early partners include midlife care providers Alloy, Gennev, Wisp, and Pomelo; primary care providers Maven, Tia, and Xella; and hormone and biomarker tracking platforms Oova, Mira, and Hertility.
Beyond the Oura app, patients and care teams will be able to access MIS scores through partner apps and portals, while clinicians can use the reports to guide conversations around symptoms and their impact on daily life. The assessment can also be incorporated into employer-sponsored menopause benefits.
If data stays on the phone, it doesn’t fulfill our vision of showing up for our members, even when things are hard,” said Oura’s Clinical Director of Women’s Health, Dr. Chris Curry. “When that information can move with a woman into the care settings she already uses, it creates a more informed conversation between patients and clinicians.”
The move builds on Oura’s latest expansion into women’s health, with MIS positioned as part of a more connected approach to lifestage care.
“We’re moving from building individual features to building a connected, clinically informed layer that can support women across life stages,” said Curry. “Menopause is an important focus, but the larger opportunity is to understand women’s health as a continuum—where reproductive, sleep, stress, cardiovascular, and metabolic signals can be considered together. That is the direction we’re building toward: tools that help women and their clinicians see the bigger picture, to realize that all health is women’s health, not just one moment or one symptom.”
